Neoantigen

Phase I Clinical Trials Shows Promise for Personal Neoantigen Vaccine Combined OPDIVO for Melanoma, Lung & Bladder Cancer

Jul 16, 2019 | Cancer, Neoantigen, Oncology, Vaccines

Neon Therapeutics’ Personal Neoantigen Vaccine study (NT-001) demonstrated prolonged progression-free survival in advanced or metastatic melanoma, non-small cell lung cancer bladder cancers. The investigational drug, NEO-PV-01, in combination with OPDIVO (nivolumab),...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Phase I Clinical Trials Shows Promise for Personal Neoantigen Vaccine Combined OPDIVO for Melanoma, Lung & Bladder Cancer

Pin It on Pinterest